GleamWall
中文EN

MBRX Moleculin Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1659617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY79.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-55.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio1.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.37x
Accruals ratio76.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$15.89M$17.73M
SG&A expense$9.12M$8.79M
Operating income-$25.10M-$26.64M
Pretax income-$33.56M-$26.05M
Income tax$0$0
Net income-$33.56M-$26.05M
EBITDA-$25.01M-$26.52M
EPS (basic)-28.42-189.14
EPS (diluted)——
Balance sheet
Cash & equivalents$8.88M$4.28M
Current assets$9.69M$5.19M
PP&E, net$78,000$159,000
Total assets$22.13M$16.93M
Current liabilities$6.85M$5.36M
Total liabilities$7.12M$5.72M
Shareholders' equity$15.01M$11.21M
Shares outstanding159,961135,155
Cash flow statement
Operating cash flow-$22.73M-$23.86M
Capital expenditure$0$13,000
Free cash flow-$22.73M-$23.88M
Investing cash flow$0-$13,000
Financing cash flow$27.28M$4.63M
Depreciation & amortization$90,000$126,000
Stock-based compensation$1.66M$1.73M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.